ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

History

ViewRay Inc. was founded in 2009 by J. Christopher Meyer, MD and John Lafortune. The company was initially funded with $20M dollars in venture capital and has since grown to employ 200 employees as of 2018.

Mission

Our mission is to innovate, manufacture, and market world-class MR-guided radiation therapy systems to provide a superior patient experience.

Vision

Our vision is to improve the survival outcomes and quality of life for cancer patients worldwide through greater accuracy of dose delivery and tumor targeting.

Key Team

Mr. Paul Ziegler Jr., J.D. (Chief Commercial Officer)

Dr. James F. Dempsey Ph.D. (Founder & Chief Scientific Officer)

Drew Hill (Sr. VP of Operations & Devel.)

Matt Harrison (Director of Investor Relations)

Karen Hackstaff (VP of Marketing)

Mr. Robert Michael Fuchs (Chief HR Officer)

Dr. Martin Fuss M.D., Ph.D. (Chief Medical Officer)

Recognition and Awards

ViewRay has received numerous awards, including being listed on the Inc 5000 List for fastest-growing companies in 2010 and being named a “Cool Vendor” in the Medical Devices Category by Gartner in 2017.